Medicine & Life Sciences
Acute Myeloid Leukemia
56%
Allogeneic Cells
34%
Androgens
16%
Appointments and Schedules
22%
Bayes Theorem
35%
Behavior Therapy
14%
Bone Marrow Transplantation
14%
Busulfan
82%
Cell Transplantation
12%
Clinical Trials
64%
Clinical Trials, Phase I
31%
Clofarabine
15%
Cyclophosphamide
19%
Cytarabine
22%
Docetaxel
20%
Drug Therapy
32%
Esophageal Neoplasms
13%
fludarabine
58%
gemcitabine
22%
Graft vs Host Disease
17%
Granulocyte Colony-Stimulating Factor
12%
Hematopoietic Stem Cell Transplantation
32%
Homologous Transplantation
22%
Idarubicin
16%
Imatinib Mesylate
22%
Leukemia
18%
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
20%
Maximum Tolerated Dose
17%
Melphalan
41%
Multiple Myeloma
13%
Myelodysplastic Syndromes
27%
Myeloid Leukemia
12%
Neoplasms
28%
Phase II Clinical Trials
54%
Platelet-Derived Growth Factor Receptors
17%
Progression-Free Survival
34%
Prostatic Neoplasms
27%
Random Allocation
29%
Recurrence
15%
Refractory Anemia with Excess of Blasts
18%
Renal Cell Carcinoma
15%
Safety
22%
Sample Size
37%
Sarcoma
14%
Stem Cell Transplantation
46%
Survival
58%
Therapeutics
41%
Tissue Donors
17%
Transplants
24%
Vorinostat
12%
Mathematics
Acute
14%
Bayesian Design
14%
Bayesian Model
12%
Bayesian Nonparametrics
16%
Bayesian Variable Selection
12%
Biomarkers
10%
Cancer
38%
Cell
12%
Chemotherapy
18%
Clinical Trials
100%
Competing Risks
10%
Count
14%
Count Data
11%
Covariates
26%
Design
72%
Dose
76%
Dose Finding
50%
Effective Sample Size
13%
Efficacy
45%
Evaluate
11%
Evaluation
11%
Group Sequential
19%
Leukemia
17%
Model
10%
Monitoring
25%
Multiple Outcomes
12%
Oncology
19%
Optimise
15%
Phase I Trial
21%
Progression
20%
Prostate Cancer
11%
Randomisation
18%
Randomized Clinical Trial
11%
Recurrent Events
11%
Regression Model
11%
Safety
16%
Sample Size
16%
Schedule
13%
Screening
10%
Simulation Study
17%
Strategy
14%
Subgroup
18%
Survival Time
23%
Therapy
22%
Toxicity
94%
Trade-offs
11%
Transplantation
11%
Treatment Effects
13%
Two-stage Design
11%
Variable Selection
14%